Compare PTCT & WHD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | PTCT | WHD |
|---|---|---|
| Founded | 1998 | 2011 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Metal Fabrications |
| Sector | Health Care | Industrials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 5.0B | 4.4B |
| IPO Year | 2006 | 2018 |
| Metric | PTCT | WHD |
|---|---|---|
| Price | $56.37 | $56.93 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 15 | 8 |
| Target Price | ★ $100.47 | $72.22 |
| AVG Volume (30 Days) | ★ 939.5K | 646.6K |
| Earning Date | 10-29-2026 | 10-28-2026 |
| Dividend Yield | N/A | ★ 1.00% |
| EPS Growth | ★ 264.48 | 18.99 |
| EPS | ★ 0.34 | 0.19 |
| Revenue | $264,734,000.00 | ★ $1,079,051,000.00 |
| Revenue This Year | N/A | $58.09 |
| Revenue Next Year | $8.29 | $5.16 |
| P/E Ratio | ★ $171.44 | $315.21 |
| Revenue Growth | ★ 36.19 | N/A |
| 52 Week Low | $58.15 | $40.18 |
| 52 Week High | $90.87 | $74.07 |
| Indicator | PTCT | WHD |
|---|---|---|
| Relative Strength Index (RSI) | 33.38 | 39.01 |
| Support Level | N/A | $56.15 |
| Resistance Level | $69.74 | $59.25 |
| Average True Range (ATR) | 2.50 | 2.74 |
| MACD | -0.78 | -0.14 |
| Stochastic Oscillator | 1.01 | 23.44 |
PTC Therapeutics Inc is a biopharmaceutical company that discovers, develops and commercializes clinically differentiated medicines that provide benefits to children and adults living with rare disorders. Its diversified therapeutic portfolio that includes several commercial products and product candidates in various stages of development, including discovery, research and clinical stages, focused on the development of new treatments for multiple therapeutic areas for rare diseases relating to neurology and metabolism. The company views its operations and manages its business in one operating segment: life science, which is focused on the discovery, development and commercialization of the company's clinically differentiated medicines that provide benefits to patients with rare disorders.
Cactus Inc is engaged in the designing, manufacturing, and sale of wellheads and pressure control equipment. Its principal products include Cactus SafeDrill wellhead systems, conventional wellheads, and production valves among others. The company also provides mission-critical field services, including service crews to assist with the installation, maintenance, and safe handling of the wellhead and pressure control equipment, as well as repair services for equipment that it sells or rents. It sells or rents its products principally for onshore unconventional oil and gas wells that are utilized during the drilling, completion (including fracturing), and production. It has two operating segments; Pressure Control, which generates key revenue and Spoolable Technologies.